- Recruiting
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
Updated: May 23, 2022
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
Sponsor
ClinicalTrials.gov Identifier: NCT04816526
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
First Posted : March 25, 2021
Click here for details on ClinicalTrials.gov
autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes
anti-BCMA-CAR-mRNA-transfected autologous CD8+ T cells
autologous anti-BCMA-CAR-mRNA-transfected CD8-positive T cells
autologous anti-BCMA-CAR-mRNA-transfected CD8+ T cells
Descartes-08
Biological:
Descartes 08
Car T-cells
CA: University of California Irvine
Orange, California, United States, 92868
TN: Sarah Cannon Research Institute at Tennessee Oncology
Locations
United States, California
United States, Tennessee